COMP <GO>
EOLS vs OVID // FREE CASH FLOW YIELD
Evolus Inc. (NASDAQ) VS. Ovid Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EOLS 3
— OVID 6
▲ FREE CASH FLOW YIELD LEADER: OVID
LAST: $7.52 (-1.51%) • MKT CAP: $496.7M
fcf-yield
-9.20%
LAST: $2.56 (+4.49%) • MKT CAP: $500.0M
fcf-yield
-7.67%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EOLS VS. OVID)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EOLS | OVID | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -28.50% | -6.50 | OVID | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -9.20% | -7.67% | -1.53 | OVID | /fcf-yield <GO> |
| Operating Margin | -11.00% | -60.00% | +49.00 | EOLS | /operating-margins <GO> |
| Net Profit Margin | -17.40% | -60.00% | +42.60 | EOLS | /net-margins <GO> |
| Revenue Growth (YoY) | 11.60% | 180.00% | -168.40 | OVID | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 11.46 | -11.26 | OVID | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | EOLS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.1 | 56.1 | -9.98 | OVID | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $496.7M | $500.0M | -$3.3M | OVID | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EOLS REV | OVID REV | EOLS GROSS % | OVID GROSS % | EOLS FCF | OVID FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $297.2M | $7.3M | 66.3% | — | -$45.7M | -$38.3M |
| FY 2024 | $266.3M | $566.0K | 68.5% | — | -$19.5M | -$56.0M |
| FY 2023 | $202.1M | $392.0K | — | — | -$34.0M | -$45.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EOLS // BETA —
OVID // BETA —